Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Summary

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Timeline

Start

2025-02-20

Primary completion

2026-05-19

Completion

2026-05-19

Drugs

Indications